登录
 机构网站
  1. 首页
  2. 情报产品
  3. 快讯详情

《JKMS，2月24日，Virus Isolation from the First Patient with SARS-CoV-2 in Korea》

  • 来源专题：COVID-19科研动态监测
  • 编译者： zhangmin
  • 发布时间：2020-02-23

  • J Korean Med Sci. 2020 Feb 24;35(7):e84. English.

    Published online Feb 18, 2020. https://doi.org/10.3346/jkms.2020.35.e84

    © 2020 The Korean Academy of Medical Sciences.

    Virus Isolation from the First Patient with SARS-CoV-2 in Korea

    Wan Beom Park, Nak-Jung Kwon, Su-Jin Choi,Chang Kyung Kang, Pyoeng Gyun Choe,Jin Yong Kim, Jiyoung Yun, Gir-Won Lee,Moon-Woo Seong, Nam Joong Kim,Jeong-Sun Seo, and Myoung-don Oh

    Abstract

    Novel coronavirus (SARS-CoV-2) is found to cause a large outbreak started from Wuhan since December 2019 in China and SARS-CoV-2 infections have been reported with epidemiological linkage to China in 25 countries until now. We isolated SARS-CoV-2 from the oropharyngeal sample obtained from the patient with the first laboratory-confirmed SARS-CoV-2 infection in Korea. Cytopathic effects of SARS-CoV-2 in the Vero cell cultures were confluent 3 days after the first blind passage of the sample. Coronavirus was confirmed with spherical particle having a fringe reminiscent of crown on transmission electron microscopy. Phylogenetic analyses of whole genome sequences showed that it clustered with other SARS-CoV-2 reported from Wuhan.

  • 原文来源：https://jkms.org/DOIx.php?id=10.3346/jkms.2020.35.e84
4浏览量
原文链接
相关报告

  • 《JKMS，2月24日，Viral Load Kinetics of SARS-CoV-2 Infection in First Two Patients in Korea.》
    • 来源专题：COVID-19科研动态监测
    • 编译者：zhangmin
    • 发布时间：2020-02-23
    • J Korean Med Sci. 2020 Feb 24;35(7):e86. doi: 10.3346/jkms.2020.35.e86. Viral Load Kinetics of SARS-CoV-2 Infection in First Two Patients in Korea. Kim JY, Ko JH, Kim Y, Kim YJ, Kim JM, Chung YS, Kim HM, Han MG, Kim SY, Chin BS. Abstract As of February 2020, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) outbreak started in China in December 2019 has been spreading in many countries in the world. With the numbers of confirmed cases are increasing, information on the epidemiologic investigation and clinical manifestation have been accumulated. However, data on viral load kinetics in confirmed cases are lacking. Here, we present the viral load kinetics of the first two confirmed patients with mild to moderate illnesses in Korea in whom distinct viral load kinetics are shown. This report suggests that viral load kinetics of SARS-CoV-2 may be different from that of previously reported other coronavirus infections such as SARS-CoV. © 2020 The Korean Academy of Medical Sciences.
    4浏览量
    原文链接

  • 《BioRxiv，3月3日，Isolation and characterization of SARS-CoV-2 from the first US COVID-19 patient》
    • 来源专题：COVID-19科研动态监测
    • 编译者：zhangmin
    • 发布时间：2020-03-04
    • Isolation and characterization of SARS-CoV-2 from the first US COVID-19 patient Jennifer Harcourt, Azaibi Tamin, Xiaoyan Lu, Shifaq Kamili, Senthil Kumar Sakthivel, Lijuan Wang, Janna Murray, Krista Queen, Brian Lynch, Brett Whitaker, Ying Tao, Clinton Paden, Jing Zhang, Yan Li, Anna Uehara, Haibin Wang, Cynthia Goldsmith, Hannah Bullock, Rashi Gautam, Craig Schindewolf, Kumari G. Lokugamage, Diona Scharton, Jessica Plante, Divya Mirchandani, Stephen Widen, Krishna Narayanan, Shinji Makino, Thomas Ksiazek, Kenneth S. Plante, Scott Weaver, Vineet D. Menachery, Natalie J. Thornburg doi: https://doi.org/10.1101/2020.03.02.972935 Abstract The etiologic agent of the outbreak of pneumonia in Wuhan China in January-2020, was identified as severe acute respiratory syndrome associated coronavirus 2 (SARS-CoV-2) . The first US patient was diagnosed by the State of Washington and the US Centers for Disease Control and Prevention on January 20, 2020. We isolated virus from nasopharyngeal and oropharyngeal specimens, and characterized the viral sequence, replication properties, and cell culture tropism. We found that the virus replicated to high titers in Vero-CCL81 cells and Vero E6 cells in the absence of trypsin. We also deposited the virus into two virus repositories, making it broadly available to the public health and research communities. We hope that open access to this important reagent will expedite development of medical countermeasures. *注，本文为预印本论文手稿，是未经同行评审的初步报告，其观点仅供科研同行交流，并不是结论性内容，请使用者谨慎使用.
    17浏览量
    原文链接